Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.

British journal of cancer ·Vol. 50 ·No. 3 ·1984-09-00 ·Pages 357-61

Dowsett M, Harris AL, Smith IE, Jeffcoate SL

Abstract

By analogy with combination chemotherapy, endocrine agents with different mechanisms of action have been combined in the treatment of patients with advanced breast cancer. The clinical use of tamoxifen+aminoglutethimide+hydrocortisone showed no clinical benefit over the individual use of tamoxifen or aminoglutethimide+hydrocortisone. The endocrine changes occurring in postmenopausal patients as a consequence of their treatment with tamoxifen+aminoglutethimide+hydrocortisone have been examined. Suppression of gonadotrophin and oestrogen levels and increased levels of sex hormone binding globulin were observed. These changes might be expected to be of benefit in the treatment of advanced breast cancer, and do not explain the lack of clinical benefit in combining the treatments. Non-responders to this combination therapy had higher levels of oestrone and dehydroepiandrosterone sulphate whilst on treatment than responders, confirming previous observations in patients treated with aminoglutethimide+hydrocortisone.

MeSH Terms

Aminoglutethimide/administration & dosage Androgens/blood Antineoplastic Combined Chemotherapy Protocols/therapeutic use Breast Neoplasms/blood,drug therapy Estrogens/blood Female Gonadotropins, Pituitary/blood Humans Hydrocortisone/administration & dosage Menopause Sex Hormone-Binding Globulin/analysis Tamoxifen/administration & dosage

Chemicals

Androgens Estrogens Gonadotropins, Pituitary Sex Hormone-Binding Globulin Tamoxifen Aminoglutethimide Hydrocortisone

Authors & Affiliations

4 authors, click to expand affiliations / ORCID

Dowsett M

Harris A L

Smith I E

Jeffcoate S L

References (24)

24 references, click to expand

Dehydroepiandrosterone and dehydroepiandrosterone sulfate dynamics in obesity.
Can J Biochem. 1975 Feb;53(2):215-22 PMID: 123823
Comparison of the biological effects of tamoxifen and a new antioestrogen (LY 117018) on the immature rat uterus.
J Endocrinol. 1983 Dec;99(3):447-53 PMID: 6644235
Plasma hormones in patients with advanced breast cancer treated with tamoxifen.
Eur J Cancer. 1976 Sep;12(9):719-23 PMID: 971694
Recurrent breast cancer treated with the antioestrogen tamoxifen: correlation between hormonal changes and clinical course.
Br Med J. 1977 Feb 12;1(6058):425-8 PMID: 837137
Assessment of response to therapy in advanced breast cancer.
Br J Cancer. 1977 Mar;35(3):292-8 PMID: 856236
Sex-hormone-binding globulin.
Clin Endocrinol (Oxf). 1974 Jan;3(1):69-96 PMID: 4134992
Study of steroid-protein binding by a novel "two-tier" column employing Cibacron Blue F3G-A-Sepharose 4B. I-Sex hormone binding globulin.
J Steroid Biochem. 1977 Sep;8(9):977-83 PMID: 562455
Increases in steroid binding globulins induced by tamoxifen in patients with carcinoma of the breast.
J Endocrinol. 1978 Feb;76(2):219-26 PMID: 564384
Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer.
Am J Obstet Gynecol. 1978 Feb 15;130(4):448-55 PMID: 629289
The conversion of androstenedione to oestrone and production of oestrone in women with endometrial cancer.
J Steroid Biochem. 1979 Jul;11(1C):905-11 PMID: 491651
Steroid hormone receptors in breast cancer treatment strategy.
Recent Prog Horm Res. 1980;36:135-56 PMID: 6251517
Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses.
Cancer Res. 1982 Aug;42(8 Suppl):3397s-3401s PMID: 7083205
Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma.
Cancer Res. 1982 Aug;42(8 Suppl):3430s-3433s PMID: 7044525
A standardised multicentre procedure for plasma gonadotrophin radioimmunoassay.
Ann Clin Biochem. 1982 Sep;19(Pt 5):358-61 PMID: 6814336
Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma.
J Clin Endocrinol Metab. 1978 Dec;47(6):1257-65 PMID: 263348
Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
Br J Cancer. 1983 May;47(5):621-7 PMID: 6221746
Combination treatment with tamoxifen and aminoglutethimide in advanced breast cancer.
Br Med J (Clin Res Ed). 1983 May 21;286(6378):1615-6 PMID: 6405912
Prognostic significance of serum prolactin levels in advanced breast cancer.
Br J Cancer. 1983 Jun;47(6):763-9 PMID: 6860546
Aminoglutethimide dose and hormone suppression in advanced breast cancer.
Eur J Cancer Clin Oncol. 1983 Apr;19(4):493-8 PMID: 6222901
1. Estrogen antagonists. Aromatase inhibitors, their pharmacology and application.
J Steroid Biochem. 1983 Jul;19(1A):53-8 PMID: 6887872
Cellular and molecular mechanism of action of antiestrogens.
J Steroid Biochem. 1983 Jul;19(1A):69-74 PMID: 6887874
Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer.
Br J Cancer. 1983 Oct;48(4):585-94 PMID: 6684948
Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy.
J Clin Endocrinol Metab. 1984 Jan;58(1):99-104 PMID: 6227629
The hormonal activity of the postmenopausal ovary.
J Clin Endocrinol Metab. 1976 Feb;42(2):247-53 PMID: 177438

Article Info

Journal

British journal of cancer

Abbr.

Br J Cancer

ISSN

0007-0920

DOI

10.1038/bjc.1984.183

Published

1984-09-00

Pages

357-61

Language

English

Region

England

NLM ID

0370635

PMCID

PMC1976801

Subset

External Links

PubMed source DOI: 10.1038/bjc.1984.183 PMC Full Text View journal details

Analysis Services

Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.

Contact

WeChat Official Account